News

Should You Buy Gilead Stock At $110?
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
BioSpace11d
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
STAT1d
Pharmalittle: We’re reading about FDA forcing out top gene therapy regulator, Gilead’s HIV challenges and more
And more pharma news updates from Pharmalittle.
Fierce Biotech12d
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
Morningstar3d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Fierce Pharma3d
FDA signs off on Gilead’s landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.
CSRWire3d
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...